Alto Neuroscience, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ANRO New York 2830 www.altoneuroscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Alto Neuroscience, Inc.

Alto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research Award - May 15th, 2026 6:27 am
Alto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business Highlights - May 13th, 2026 5:03 am
Alto Neuroscience Announces Participation in Upcoming Investor Conferences - May 11th, 2026 2:05 pm
Alto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual Meeting - May 4th, 2026 6:03 am
Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression - Apr 21st, 2026 6:03 am
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss - Apr 2nd, 2026 2:10 pm
Sector Update: Health Care Stocks Softer Late Afternoon - Apr 2nd, 2026 1:57 pm
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data - Apr 2nd, 2026 12:36 pm
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM - Apr 2nd, 2026 6:20 am
Alto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline Advancements - Apr 1st, 2026 2:30 pm
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement - Mar 23rd, 2026 9:14 am
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207 - Mar 23rd, 2026 6:55 am
Alto Neuroscience Announces $120 Million Private Placement Financing - Mar 16th, 2026 5:03 am
Alto Neuroscience Reports Full Year 2025 Financial Results and Recent Business Highlights - Mar 16th, 2026 4:03 am
Alto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS Forum - Mar 13th, 2026 6:03 am
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight - Mar 11th, 2026 3:31 pm
Alto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with Schizophrenia - Feb 13th, 2026 6:04 am
Alto Neuroscience, Inc.'s (NYSE:ANRO) Intrinsic Value Is Potentially 58% Above Its Share Price - Feb 5th, 2026 4:20 am
Alto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and Treatment - Feb 3rd, 2026 6:27 am
Alto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in Depression - Jan 14th, 2026 5:27 am